Research Grade Anti-Human CD19 (JCAR014) (HB996236)

Fiche technique Partager le produit Copier les informations

Prix(USD) : $

Spécification :

100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique

Aperçu

Numéro de catalogue	HB996236
Description	Anti-Human CD19 (JCAR014) (HB996236) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Isotype	IgG
ID de clone	JCAR014
Système d'expression	Mammalian Cells
Clonalité	Monoclonal
Cible	CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Niveau d'endotoxines	Please contact the lab for this information.
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P15391
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Noms alternatifs	JCAR014
Contexte	B-lymphocyte antigen CD19 is a ~61 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi). 1. Vanshylla, K. et al. (2018) Scientific reports 8, 4244. PMID: 29523808 2. Carter, RH. et al. (1992) Science (New York, N.Y.) 256, 105-7. PMID: 1373518 3. van Zelm, MC. et al. (2006) The New England journal of medicine 354, 1901-12. PMID: 16672701 4. de Rie, MA. et al. (1989) Cellular immunology 118, 368-81. PMID: 2463100 5. Wang, Y. et al. (2002) Immunity 17, 501-14. PMID: 12387743 6. Sato, S. et al. (1997) Journal of immunology (Baltimore, Md. : 1950) 159, 3278-87. PMID: 9317126 7. Buhl, AM. et al. (1997) The Journal of experimental medicine 186, 1897-910. PMID: 9382888
Note	For research use only. Not suitable for clinical or therapeutic use.